VALEANT PHARMACEUTICALS INTERNATIONAL TO ACQUIRE BAUSCH + LOMB FOR $8.7 BILLION
Valeant Pharmaceuticals International and Bausch + Lomb Holdings Incorporated have entered into a definitive agreement under which Valeant will acquire Bausch + Lomb for $8.7 billion in cash.
Under the terms of the agreement, Valeant will pay $ 8.7 billion in cash, of which approximately $4.5 billion will go to an investor group led by Warburg Pincus and approximately $4.2 billion will be used to repay Bausch + Lomb's outstanding debt.
Bausch + Lomb will retain its name and become a division of Valeant. Valeant's existing ophthalmology businesses will be integrated into the Bausch + Lomb division.
www.bausch.com
Latest Articles
Organising for Success
Professional and personal goals drive practice ownership and operational choices.
Update on Astigmatism Analysis
Is Frugal Innovation Possible in Ophthalmology?
Improving access through financially and environmentally sustainable innovation.
iNovation Innovators Den Boosts Eye Care Pioneers
New ideas and industry, colleague, and funding contacts among the benefits.
José Güell: Trends in Cornea Treatment
Endothelial damage, cellular treatments, human tissue, and infections are key concerns on the horizon.
Making IOLs a More Personal Choice
Surgeons may prefer some IOLs for their patients, but what about for themselves?
Need to Know: Higher-Order Aberrations and Polynomials
This first instalment in a tutorial series will discuss more on the measurement and clinical implications of HOAs.
Never Go In Blind
Novel ophthalmic block simulator promises higher rates of confidence and competence in trainees.
Simulators Benefit Surgeons and Patients
Helping young surgeons build confidence and expertise.